# Molecular Partners (MOLN) — News MOLN · NASDAQ · Stock Canonical page: https://www.lighthorse.io/tickers/moln/news ## Recent headlines - [Biocon's Shaw: Biosimilars a very attractive segment](https://www.ainvest.com/news/biocon-shaw-biosimilars-attractive-segment-2610) — AInvest Wire, Oct 13, 2026 Biocon, India’s largest biopharmaceutical company, has positioned itself as a key player in the global biosimilars market, with its chairman and managing director, Kiran Mazumdar-Shaw, emphasizing the segment’s growing potential. The company recently received approval for its Glargine biosimilar in… - [Molecular Partners AG: cash position of CHF 67.9 million as of June 30, 2026, expected to fund operations into late 2027](https://www.ainvest.com/news/molecular-partners-ag-cash-position-chf-67-9-million-june-30-2026-expected-fund-operations-late-2027-2608) — AInvest Wire, Aug 25, 2026 - [Molecular Partners AG: Maintains previously reported FY forecast total operating expenses](https://www.ainvest.com/news/molecular-partners-ag-maintains-previously-reported-fy-forecast-total-operating-expenses-2608) — AInvest Wire, Aug 25, 2026 Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) has maintained its previously reported full-year 2025 forecast for total operating expenses, aligning with its guidance of CHF 55–65 million at constant exchange rates. The company’s 2025 Annual Report, published in March 2026, confirmed that… - Molecular spikes 5% as the Co. to provide updates at 42nd annual JPM Healthcare conference — AInvest Wire, Jan 8, 2024 --- Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express. This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness. Data provided by [AInvest](https://www.ainvest.com).